The RELY STUDY: Patients with r/r Diffuse Large B-Cell Lymphoma
Research type
Research Study
Full title
The RELY STUDY: A retrospective database analysis of the epidemiology, patient characteristics, treatment pathway, resource utilisation and clinical outcomes of patients with r/r Diffuse Large B-Cell Lymphoma in England.
IRAS ID
292723
Contact name
John Were
Contact email
Sponsor organisation
Health iQ Limited
Duration of Study in the UK
1 years, 2 months, 1 days
Research summary
Lymphoma is a type of blood cancer that develops when white blood cells grow out of control. There are wo types of Lymphomas namely Hodgkin Lymphoma (presence of abnormal Reed-Sternberg cells) and non-Hodgkin Lymphoma (NHL – absence of abnormal Reed-Sternberg cells). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL.
Being a common and debilitating disease, it is important to understand how much resources patients with DLBCL use up in the National Health Service, as well as the various treatments they undergo, and how those treatments impact their survival. This is especially true of DLBCL that is treated with recommended medications but then reappears. This study aims to use pseudonymized data from Public Health England cancer and tumour registry (CAS) dataset to construct a group of patients with DLBCL. Using the same dataset linked to the cancer treatment datasets (systemic anticancer therapy or SACT, surgery in secondary care through the hospital episode statistics dataset or HES, radiotherapy through the radiotherapy dataset or RTDS), the study would determine treatment pathways. The span of time covered would be from 2012 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reconfigure services to provide better treatment pathways for patients.REC name
London - City & East Research Ethics Committee
REC reference
20/PR/0859
Date of REC Opinion
14 Jan 2021
REC opinion
Favourable Opinion